XNAS · Healthcare · Biotechnology
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | Q2 2026 | -1.14 | -0.93 | +18.42% | $73.7M | ✅ Beat | -0.83% | +2.23% | — |
| 2026-02-05 | Q1 2026 | 0.02 | 0.22 | +1000.00% | $264.0M | ✅ Beat | -0.99% | -3.50% | -7.46% |
| 2025-11-25 |
| Q4 2025 |
| -0.05 |
| -0.18 |
| -260.00% |
| $256.5M |
| ❌ Miss |
| — |
| — |
| — |
| 2025-02-10 | Q1 2025 | -0.72 | -1.39 | -93.06% | $2.5M | ❌ Miss | -5.17% | +2.61% | -20.83% |
| 2024-11-26 | Q4 2024 | -0.92 | -1.37 | -48.91% | $0 | ❌ Miss | +24.23% | +23.85% | -7.22% |
| 2024-08-08 | Q3 2024 | -0.55 | -1.38 | -150.91% | $0 | ❌ Miss | -9.44% | -12.34% | -15.82% |
| 2024-02-06 | Q1 2024 | -0.82 | -1.24 | -51.22% | $3.6M | ❌ Miss | — | — | — |
| 2023-11-29 | Q4 2023 | -0.60 | -1.02 | -70.00% | $16.1M | ❌ Miss | -26.85% | -17.91% | +5.59% |
Showing last 8 quarters.